Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer

被引:0
作者
K J O'Byrne
M I Koukourakis
A Giatromanolaki
G Cox
H Turley
W P Steward
K Gatter
A L Harris
机构
[1] Leicester Royal Infirmary,University Department of Oncology
[2] Laboratory of Cancer Biology,Department of Radiotherapy & Oncology
[3] University Hospital of Iraklion,Department of Cellular Science
[4] Oxford Radcliffe Hospitals Trust,Department of Imperial Cancer Research Fund Medical Oncology Unit
[5] Oxford Radcliffe Hospitals Trust,undefined
来源
British Journal of Cancer | 2000年 / 82卷
关键词
vascular endothelial growth factor; platelet-derived endothelial cell growth factor; angiogenesis; non-small cell lung cancer;
D O I
暂无
中图分类号
学科分类号
摘要
High microvessel density, an indirect measure of angiogenesis, has been shown to correlate with increased tumour size, lymph node involvement and poor prognosis in non-small-cell lung cancer (NSCLC). Tumour cell vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PD-ECGF) expression correlate with angiogenesis and a poor outcome in this disease. In a retrospective study VEGF and PD-ECGF expression and microvessel density were evaluated immunohistochemically in surgically resected specimens (T1–3, N0–2) from 223 patients with operable NSCLC using the VG1, P-GF.44C and JC70 monoclonal antibodies respectively. High VEGF immunoreactivity was seen in 104 (46.6%) and PD-ECGF in 72 (32.3%) cases and both were associated with high vascular grade tumours (P = 0.009 and P = 0.05 respectively). Linear regression analysis revealed a weak positive correlation between VEGF and PD-ECGF expression in cancer cells (r = 0.21;P = 0.002). Co-expression of VEGF and PD-ECGF was not associated with a higher microvessel density than VEGF or PD-ECGF only expressing tumours. Furthermore a proportion of high vascular grade tumours expressed neither growth factor. Univariate analysis revealed tumour size, nodal status, microvessel density and VEGF and PD-ECGF expression as significant prognostic factors. Tumour size (P< 0.02) and microvessel density (P< 0.04) remained significant on multivariate analysis. In conclusion, VEGF and PD-ECGF are important angiogenic growth factors and have prognostic significance in NSCLC. Furthermore the study underlines the prognostic significance of microvessel density in operable NSCLC. © 2000 Cancer Research Campaign
引用
收藏
页码:1427 / 1432
页数:5
相关论文
共 270 条
  • [1] Amaya H(1997)Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet derived endothelial cell growth factor expression in human colorectal cancer Cancer Lett 119 227-235
  • [2] Tanigawa N(1997)Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularisation in patients with radically resected non-small cell lung cancer J Clin Oncol 15 2456-2466
  • [3] Lu C(1997)The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer J Leukoc Biol 62 554-562
  • [4] Matsumura M(1998)Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine J Clin Oncol 16 1795-1802
  • [5] Shimomatsuya T(1997)Relationship between vascularity, age and survival in non-small cell lung cancer Br J Cancer 76 1367-1375
  • [6] Horiuchi T(1997)The biology of vascular endothelial growth factor Endoc Rev 18 4-25
  • [7] Muraoka R(1997)Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma: a prospective study J Natl Cancer Inst 89 881-886
  • [8] Apolinario RM(1999)Expression of vascular endothelial growth factor mRNA in non-small cell lung carcinomas Br J Cancer 79 363-369
  • [9] van der Valk P(1995)Quantification and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count and computer image analysis J Pathol 177 275-283
  • [10] de Jong JS(1997)Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF Ann Oncol 8 271-275